USOR 24186- Ph3 multicenter study of MK2870 in subjects with ovarian cancer (GOG-3102)

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy

Disease Types: Gynecological/Ovarian

Available at: Arlington Heights, Chicago, Niles